Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9

Cholangiocarcinoma (CCA) is a highly invasive cancer, diagnosed at an advanced stage, and refractory to surgical intervention and chemotherapy. Cyclin-dependent kinases (CDKs) regulate cell cycle progression and transcriptional processes, and are considered potential therapeutic targets for cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Saqub, Hera, Proetsch-Gugerbauer, Hannah, Bezrookove, Vladimir, Nosrati, Mehdi, Vaquero, Edith M., de Semir, David, Ice, Ryan J., McAllister, Sean, Soroceanu, Liliana, Kashani-Sabet, Mohammed, Osorio, Robert, Dar, Altaf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595101/
https://www.ncbi.nlm.nih.gov/pubmed/33116269
http://dx.doi.org/10.1038/s41598-020-75578-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595101/
https://www.ncbi.nlm.nih.gov/pubmed/33116269
http://dx.doi.org/10.1038/s41598-020-75578-5

Ejemplares similares